1 Weight Loss Pharma Stock to Buy, and 1 to Consider
If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the pie, there's more than one company that could experience dramatic growth in the next few years and beyond.
On that note, let's examine one of the segment's leaders that's worth buying now, and one of the smaller players with an interesting business model that might pay off for its shareholders in the long run.
Eli Lilly (NYSE: LLY) and its chief competitor Novo Nordisk are the two undisputed champions of the weight loss market today.
Source Fool.com
